Epithelial growth factor receptor (EGFR) is a transmembrane protein with tyrosine kinase activity, and NSCLC patients with mutations or overexpression of the EGFR kinase structural domain can be targeted by EGFR-tyrosine kinase inhibitor (EGFR-TKI), such as gefitinib [112]. Here, EGFR is linked to non-small cell lung carcinoma.